Phibro Animal Health (PAHC)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-04
$35.40-10.22%
Close 2026-11-05 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-04
QuarterlyIQ Insights · PAHC
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 | Jun 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||
| Revenues | 1,541.0 | 1,518.1 | 1,296.2 | 1,017.7 | 977.9 | 942.3 | 833.4 | 800.4 | 828.0 | 820.0 | 764.3 | 751.5 | 748.6 | 691.9 |
| Total Revenues | — | — | — | — | — | — | 833.4 | 800.4 | — | 820.0 | 764.3 | 751.5 | 748.6 | 691.9 |
| Cost of Revenues | 1,019.7 | 1,005.6 | 896.3 | 704.6 | 679.7 | 656.9 | 562.0 | 543.5 | 563.4 | 553.1 | — | — | — | — |
| Gross Profit | 521.3 | 512.5 | 399.9 | 313.1 | 298.2 | 285.4 | 271.4 | 256.9 | 264.6 | 266.9 | 248.2 | 239.0 | 233.3 | 204.4 |
| Operating Expenses & Income | ||||||||||||||
| Selling, General & Admin | 328.5 | 318.1 | 289.5 | 259.8 | 226.4 | 206.4 | 196.5 | 187.7 | 181.4 | 168.0 | 150.3 | 153.3 | 145.6 | 140.6 |
| R&D Expenses | — | 24.6 | 23.7 | 29.2 | 24.4 | 20.8 | 17.8 | 13.7 | 12.1 | 10.0 | 9.4 | 11.0 | 9.5 | 8.2 |
| Operating Income | 192.8 | 194.4 | 110.5 | 53.3 | 71.8 | 79.0 | 74.9 | 69.2 | 83.2 | 98.9 | 97.9 | 85.7 | 87.7 | 63.8 |
| Earnings from Continuing Operations | ||||||||||||||
| Interest Expense | — | 46.4 | 37.2 | 23.0 | 18.7 | 12.7 | 13.7 | 14.6 | — | — | — | — | 14.6 | 29.9 |
| Interest & Investment Income | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.1 |
| Net Interest Expenses | — | — | — | — | — | — | — | — | — | — | — | — | — | 29.8 |
| Asset Writedown | — | — | 5.3 | — | — | — | — | — | — | — | — | — | — | — |
| EBT, Incl. Unusual Items | 139.9 | 137.3 | 68.0 | 10.9 | 54.1 | 72.3 | 66.5 | 55.5 | 71.5 | 88.1 | 80.5 | 76.8 | 78.8 | 6.3 |
| Income Tax Expense | 37.1 | 37.6 | 19.7 | 8.5 | 21.5 | 23.2 | 12.1 | 22.0 | 16.8 | 23.2 | 15.9 | (6.0) | 18.5 | 9.4 |
| Net Income | ||||||||||||||
| Net Income | 102.7 | 99.7 | 48.3 | 2.4 | 32.6 | 49.2 | 54.4 | 33.6 | 54.7 | 64.9 | 64.6 | 82.7 | 60.3 | (3.1) |
| Per Share | ||||||||||||||
| Basic EPS | 2.53 | 2.46 | 1.19 | 0.06 | 0.81 | 1.21 | 1.34 | 0.83 | 1.35 | 1.61 | 1.63 | 2.11 | 1.55 | — |
| Diluted EPS | 2.51 | 2.43 | 1.19 | 0.06 | 0.81 | 1.21 | 1.34 | 0.83 | 1.35 | 1.61 | 1.61 | 2.07 | 1.51 | — |
| Revenue per Share | 37.62 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividend per Share | — | 0.48 | 0.48 | 0.48 | 0.48 | 0.48 | 0.48 | 0.48 | — | 0.40 | 0.40 | 0.40 | 0.40 | 0.82 |
| Basic Weighted Avg Shares | 40.6 | 40.5 | 40.5 | 40.5 | 40.5 | 40.5 | 40.5 | 40.5 | 0.0 | 0.0 | 0.0 | 0.0 | 39.0 | — |
| Diluted Weighted Avg Shares | 41.0 | 41.0 | 40.7 | 40.5 | 40.5 | 40.5 | 40.5 | 40.5 | 0.0 | 0.0 | 0.0 | 0.0 | 39.8 | — |
| Supplemental | ||||||||||||||
| EBITDA | — | 245.9 | 156.1 | 89.5 | 105.9 | 111.7 | 106.8 | 101.5 | 110.8 | 125.9 | 123.9 | 109.2 | 109.3 | 85.2 |
| EBIT | 192.8 | 194.4 | 110.5 | 53.3 | 71.8 | 79.0 | 74.9 | 69.2 | 83.2 | 98.9 | 97.9 | 85.7 | 87.7 | 63.8 |
| Effective Tax Rate | 26.6% | — | — | — | 39.7% | 32.0% | 18.2% | 39.6% | 23.5% | 26.3% | 19.8% | -7.8% | 23.5% | 149.6% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.